Imugene Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IUGNF research report →
Price Chart
About the company
Imugene Limited, an Australian firm specializing in clinical-stage immuno-oncology, is dedicated to conceiving diverse immunotherapies. Its core mission involves activating the immune systems of cancer patients to effectively combat and eradicate malignant growths. The company's primary therapeutic candidate is HER-Vaxx, a vaccine engineered for HER2-positive cancers.
- CEO
- Leslie Chong
- IPO
- 2019
- Employees
- 14
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on IUGNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.17M
- P/E
- -0.13
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 1.63
- EV/EBITDA
- -0.34
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -414.10%
- ROIC
- -477.75%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-6,834,408-255.4%
- Op Income
- $-74,847,280
- Net Income
- $-105,189,232-52.4%
- EPS
- $-0.32+0.0%
- OCF Growth
- +40.7%
- FCF Growth
- +50.2%
- 52W High
- $0.31
- 52W Low
- $0.02
- 50D MA
- $0.06
- 200D MA
- $0.12
- Beta
- 2.08
- RSI (14)
- 44
- Avg Volume
- 22.57K
No earnings-call transcripts are available for IUGNF yet.
- Free Float
- 56.8%
- Shares Outstanding
- 489.72M
- Float Shares
- 278.08M
Our IUGNF coverage
Recent articles, reports, and earnings notes.
No research on IUGNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IUGNF report →Figma shares rise as Bank of America resumes coverage with a ‘Buy’ rating
proactiveinvestors.com · Jul 7
Imugene raises $11.1 million to advance azer-cel after complete responses in early cohort
proactiveinvestors.com · Jul 7
Shell flags 'significantly higher' gas trading and sells South Africa business - UPDATE
proactiveinvestors.com · Jul 7
Imugene reports second BTKi cohort response - ICYMI
proactiveinvestors.com · Jul 4
Imugene CEO details azer-cel trial milestone - ICYMI
proactiveinvestors.com · Jul 3
Anthropic clears export hurdle for Fable 5, easing a threat to its IPO story
proactiveinvestors.com · Jul 1
Imugene reports second complete response in azer-cel BTKi cohort
proactiveinvestors.com · Jul 1
Fed may adopt leaner communications strategy under Warsh, says Deutsche Bank
proactiveinvestors.com · Jul 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.